Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 12:20 PM
Ignite Modification Date: 2025-12-25 @ 12:03 PM
NCT ID: NCT00393861
Description: None
Frequency Threshold: 5
Time Frame: beginning of treatment until the end of the study for up to 5 years
Study: NCT00393861
Study Brief: Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Oxaliplatin & Bevacizumab Bevacizumab and Oxaliplatin: Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes None None 0 29 15 29 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
CONSTIPATION SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (9.0) View
HEARTBURN/DYSPEPSIA SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (9.0) View
TASTE ALTERATION (DYSGEUSIA) SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (9.0) View
VOMITING SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (9.0) View
FEVER (IN THE ABSENCE OF NEUTROPENIA, WHERE NEUTROPENIA IS DEFINED AS ANC <1.0 X 10E9/L) SYSTEMATIC_ASSESSMENT General disorders MedDRA (9.0) View
INJECTION SITE REACTION/EXTRAVASATION CHANGES SYSTEMATIC_ASSESSMENT General disorders MedDRA (9.0) View
HEMORRHAGE, PULMONARY/UPPER RESPIRATORY - NOSE SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (9.0) View
ANOREXIA SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA (9.0) View
DIZZINESS SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (9.0) View
NEUROPATHY: SENSORY SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (9.0) View
MOOD ALTERATION - DEPRESSION SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA (9.0) View
PAIN - HEAD/HEADACHE SYSTEMATIC_ASSESSMENT General disorders MedDRA (9.0) View
PAIN - ABDOMEN NOS SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (9.0) View
DYSPNEA (SHORTNESS OF BREATH) SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (9.0) View
PRURITUS/ITCHING SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (9.0) View
HYPERTENSION SYSTEMATIC_ASSESSMENT Vascular disorders MedDRA (9.0) View
NAUSEA SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (9.0) View
FATIGUE (ASTHENIA, LETHARGY, MALAISE) SYSTEMATIC_ASSESSMENT General disorders MedDRA (9.0) View
PAIN - OTHER SYSTEMATIC_ASSESSMENT General disorders MedDRA (9.0) View
INSOMNIA SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (9.0) View
COUGH SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (9.0) View